These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 21649536)

  • 1. Abatacept: a biologic immune modulator for rheumatoid arthritis.
    Papagoras C; Drosos AA
    Expert Opin Biol Ther; 2011 Aug; 11(8):1113-29. PubMed ID: 21649536
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Abatacept in biologic-naïve patients and TNF inadequate responders: clinical data in focus.
    Sherrer Y
    Curr Med Res Opin; 2008 Aug; 24(8):2283-94. PubMed ID: 18590608
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of abatacept in the management of rheumatoid arthritis.
    Nogid A; Pham DQ
    Clin Ther; 2006 Nov; 28(11):1764-78. PubMed ID: 17212998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Indirect treatment comparison of abatacept with methotrexate versus other biologic agents for active rheumatoid arthritis despite methotrexate therapy in the United kingdom.
    Guyot P; Taylor PC; Christensen R; Pericleous L; Drost P; Eijgelshoven I; Bergman G; Lebmeier M
    J Rheumatol; 2012 Jun; 39(6):1198-206. PubMed ID: 22505698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety profile of abatacept in rheumatoid arthritis: a review.
    Khraishi M; Russell A; Olszynski WP
    Clin Ther; 2010 Oct; 32(11):1855-70. PubMed ID: 21095481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and patient-reported outcomes in clinical trials of abatacept in the treatment of rheumatoid arthritis.
    Massarotti EM
    Clin Ther; 2008 Mar; 30(3):429-42. PubMed ID: 18405783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of abatacept in biologic-naïve patients with active rheumatoid arthritis.
    Schiff M; Bessette L
    Clin Rheumatol; 2010 Jun; 29(6):583-91. PubMed ID: 20099018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study.
    Weinblatt M; Combe B; Covucci A; Aranda R; Becker JC; Keystone E
    Arthritis Rheum; 2006 Sep; 54(9):2807-16. PubMed ID: 16947384
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abatacept in the treatment of rheumatoid arthritis.
    Todd DJ; Costenbader KH; Weinblatt ME
    Int J Clin Pract; 2007 Mar; 61(3):494-500. PubMed ID: 17313619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Abatacept: a novel treatment for moderate-to-severe rheumatoid arthritis.
    Reynolds J; Shojania K; Marra CA
    Pharmacotherapy; 2007 Dec; 27(12):1693-701. PubMed ID: 18041889
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Greater remission rates in patients with early versus long-standing disease in biologic-naive rheumatoid arthritis patients treated with abatacept: a post hoc analysis of randomized clinical trial data.
    Yazici Y; Moniz Reed D; Klem C; Rosenblatt L; Wu G; Kremer JM
    Clin Exp Rheumatol; 2011; 29(3):494-9. PubMed ID: 21722499
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Efficacy and safety of abatacept in patients with rheumatoid arthritis and no prior treatment with biologics].
    Escudero Contreras A; Castro-Villegas MC; Hernández-Hernández MV; Díaz-González F
    Reumatol Clin; 2011; 7(6):392-6. PubMed ID: 22078698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy.
    Genovese MC; Schiff M; Luggen M; Becker JC; Aranda R; Teng J; Li T; Schmidely N; Le Bars M; Dougados M
    Ann Rheum Dis; 2008 Apr; 67(4):547-54. PubMed ID: 17921185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved health-related quality of life for rheumatoid arthritis patients treated with abatacept who have inadequate response to anti-TNF therapy in a double-blind, placebo-controlled, multicentre randomized clinical trial.
    Westhovens R; Cole JC; Li T; Martin M; Maclean R; Lin P; Blaisdell B; Wallenstein GV; Aranda R; Sherrer Y
    Rheumatology (Oxford); 2006 Oct; 45(10):1238-46. PubMed ID: 16567357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy results from pivotal clinical trials with abatacept.
    Rozelle AL; Genovese MC
    Clin Exp Rheumatol; 2007; 25(5 Suppl 46):S30-4. PubMed ID: 17977486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective costimulation modulation with abatacept: a look at quality-of-life outcomes in patients with rheumatoid arthritis.
    Shergy WJ
    Semin Arthritis Rheum; 2009 Jun; 38(6):434-43. PubMed ID: 18538830
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Remission in rheumatoid arthritis: wishful thinking or clinical reality?
    Sesin CA; Bingham CO
    Semin Arthritis Rheum; 2005 Dec; 35(3):185-96. PubMed ID: 16325659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic agents for patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor-alpha antagonists.
    Isaacs JD
    Expert Opin Biol Ther; 2009 Dec; 9(12):1463-75. PubMed ID: 19916731
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of rheumatoid arthritis patients with abatacept and methotrexate significantly improved health-related quality of life.
    Emery P; Kosinski M; Li T; Martin M; Williams GR; Becker JC; Blaisdell B; Ware JE; Birbara C; Russell AS
    J Rheumatol; 2006 Apr; 33(4):681-9. PubMed ID: 16568505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Abatacept: A Review in Rheumatoid Arthritis.
    Blair HA; Deeks ED
    Drugs; 2017 Jul; 77(11):1221-1233. PubMed ID: 28608166
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.